Parkinson's sleep study halted early – what we know
NCT ID NCT03968744
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether the drug safinamide (Xadago) could improve sleep quality in people with Parkinson's disease. Eleven participants took safinamide for 12 weeks while their sleep was measured. The trial was terminated early, so the results are not conclusive.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- safinamide (Xadago)
- What this could lead to
- If it works, this could point toward a treatment for sleep problems in Parkinson's disease.
- What could go wrong
- The trial was terminated early and had only 11 participants, so results are very limited. It is unclear if safinamide truly helps sleep.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
11 people
The number who actually took part.
- Started
-
Feb 2019
- Finished
-
Feb 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years old * Fluctuating idiopathic PD patients according to UK Brain bank Criteria * Hoehn and Year II to IV under treatment * Sleep disturbance with a Pittsburgh Sleep Quality Index (PSQI) \> 5 * Treatment with L-DOPA, alone or with other dopaminergic drugs, at a stable dose since at least 28 days prior to inclusion * Treatment with all substances potentially acting on sleep and mood must be constant since at least 28 days prior to inclusion * Written informed consent * Willingness and ability to participate in the trial Exclusion Criteria: * Off label use of safinamide * Early PD or absence of PD fluctuations * Concomitant treatment with other MAO-B inhibitors (wash-out period: at least 14 days) * Atypical Parkinsonism * Severe known sleep-related breathing disorders with any specific treatment or severe known sleep-related breathing disorders (apnoea-hypopnea index score \>30/h) with or without a specific treatment * Dementia (MoCA \< 26) * Severe depression (BDI-II ≥ 29) * Other severe psychiatric symptoms such as active psychosis or major hallucinations * Any previous or concomitant severe medical conditions or clinical laboratory abnormality which, in the clinical judgement of the Investigators, does not allow patients' participation into the study * Moderate or severe hepatic impairment, any type of retinopathy and/or any pathology that is deemed to be a contraindication according to safinamide's SmPC * Any concomitant treatment not allowed or contraindicated in the safinamide SmPC * Women who are pregnant or breast feeding * Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Idiopathic Parkinson's disease (at later stage) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Neurocenter of Southern Switzerland - Ente Ospedaliero Cantonale (EOC)
Lugano, 6900, Switzerland